Member Info for Sangijuelas1

And if get news on fast track approval of Mrx 0518 in Q1?

Meeting due with FDA.

The Nasdaq listing will also make it easier to raise capital by admitting new shares there.

On BMS and IBD

Bristol Myers Squibb is Focused on Advancing Care for Patients

At Bristol Myers Squibb, we are committed to developing transformational therapies that meet the needs of patients living with IBD. Our researchers follow the science to pursue novel targets and innovative approaches that may lead to new therapeutic options as well as disease prevention strategies. As we conduct clinical trials, we have an opportunity to deepen our understanding of IBD and analyze critical data that may offer new insights that advance research and, ultimately, care for patients.

As part of our efforts, we developed and fielded the Inflammatory Bowel Disease Global Assessment of Patients and Physician Unmet Needs Survey (IBD GAPPS) in 2019 to better understand the impact of the evolving IBD treatment landscape on the needs of patients with both UC and Crohn’s disease, as well as their doctors. Through talking with more than 2,300 patients and more than 650 gastroenterologists around the world, we gathered critical insights into patient and prescriber perceptions of unmet needs, aiming to help the IBD community take an important step forward in treating IBD.16

With our focus on transforming care for patients, we are continuing to work towards developing therapies that will lead to lasting remission for those living with immune-mediated diseases.

https://www.bms.com/life-and-science/science/understanding-needs-of-patients-living-with-ibd.html

Looking for an intern on LinkedIn- description of Discovery Biotherapeutics

The Discovery Biotherapeutics group in Redwood City, California (DBR) is focused on discovering and developing novel biotherapeutic drugs. Our mission is to design and develop biological tools and processes to enable the latest advances in biotherapeutics, and to create the next generation of drugs to support early discovery efforts. We work in cross-functional teams to understand the key scientific questions and critical needs within the discovery pipeline and support ongoing research in various disease indications throughout BMS.

Katrin was at Celgene as well

A £100 investment in Asos in 2003 would have netted £115,000 in 2013.

That's a multi bagger and why you need to hold for gold.

Bristol Myers Squibb is worth 1000 times the value of 4D.
Why are their ex VPs on the board of 4D?

would a little UK pharma have recently brought on board such heavyhitters as Axel and Katrin?

Katrin is currently senior VP at Lundbeck (mcap 38bn) which has programmes in neuro degenerative disorders including Parkinsons and Alzheimers

Katrin Rupalla held various leadership positions in drug development at Bristol Myers Squibb including Head of China development for 3 years

Ho Sung Cho is senior VP at Bristol Myers Squibb (BMS) in their Discovery Biotherapeutics team.
He joined Celgene in 2014, which was taken over by BMS in 2019.
Celgene liked to acquire companies, Receptos for 7bn in 2015 and Juno Therapeutics in 2018 for 9bn.
Throughout this period the Senior VP and Head of Clinical Research & Development Haematology Oncology at Celgene was Axel Glasmacher.

Axel Glasmacher is now non executive chairperson of 4D Pharma

Think 4D were represented at an IBD conference hosted by BMS the other day.

Got anything interesting to say about 4D? Why not start a new thread posting something useful rather than just complaining about my posts?

A lot of decent posters used to be on this board but they gave up on it around the time of the Zengah prophecies that caused it to become infested by share flippers.

Don't know who she is, do you?

This is the best possible price and long may it continue . It gives a great opportunity to buy more.
So many companies with great prospects are owned privately and this is publicly available.
Long may it remain the best kept secret on Aim

Don't know what is "difficult". Owning this company is amazing.
If you needed money for Xmas maybe you shouldn't have invested based on the prophecies of Zengah

What I post on here is my business. What you post is yours.
I don't know who appointed you as the moderator.

This is not really about 4D. It's more to do with financial planning and having investments on a suitable platform going forward.

If you really think it's a load of rubbish grab a few grand of shares in Mereo Bio Pharma which are delisting from Aim next month and see if you can hold the ADRs they are converted to in an Isa or Sipp

Also I have spoken to staff at AJ Bell. They are dealing with a lot of Verona clients at the moment with problems.
It's just something to be conscious of going forward and keeping an eye on. My preference is for the dual listing to be maintained indefinitely but in the future the board at 4D might see it differently.

Are they ADRs or are they companies that IPOd on Nasdaq? The latter is fine.
Why don't you check out some of the posts on the Verona Pharma thread over the last couple of months?